SavedAdd your journal

Journals / The European Research Journal / 2018 / Cilt: 4 - Sayı: 4

Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones

Erkan EFE
Faruk KÜÇÜKDURMAZ
Tayfun ŞAHİNKANAT
Hasan Çetin EKERBİÇER
Pages
320–325
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Themean TZ RI at baseline and after tadalafil administration were 0.4985 and 0.5497, respectively (p = 0.232).No statistically significant differences for RI changes between baseline and after the administration of a singledose 20 mg tadalafil were observed in the prostatic zones.Conclusion: A single dose 20 mg tadalafil showed no impact on prostate TZ RI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Although there are several studies addressing the efficacy of phosphodiesterase type 5 inhibitorsfor the management of benign prostatic hyperplasia-lower urinary tract symptoms (BPH-LUTS), unfortunately,there is a lack of high evidence data to support their effect at the prostate level.
📊
Key Findings & Data:The aim of this study was to evaluate theeffect of a single dose 20 mg tadalafil on resistive index value in prostate zones to evaluate the mechanism ofaction of phosphodiesterase type 5-inhibitors at the prostate level.Methods: Twenty consecutive patients aged between 54-67 years with BPH-LUTS [International ProstateSymptom Score ≥ 12] and erectile dysfunction [five-item International Index of Erectile Function (IIEF)questionnaire < 22] underwent RI measurement in prostate transitional zone (TZ) and peripheral zone (PZ)using transrectal power Doppler ultrasonography baseline and within 16 hours after the administration of 20mg tadalafil.
💡
Conclusion & Impact:Themean TZ RI at baseline and after tadalafil administration were 0.4985 and 0.5497, respectively (p = 0.232).No statistically significant differences for RI changes between baseline and after the administration of a singledose 20 mg tadalafil were observed in the prostatic zones.Conclusion: A single dose 20 mg tadalafil showed no impact on prostate TZ RI.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Although there are several studies addressing the efficacy of phosphodiesterase type 5 inhibitorsfor the management of benign prostatic hyperplasia-lower urinary tract symptoms (BPH-LUTS), unfortunately,there is a lack of high evidence data to support their effect at the prostate level. The existing studies suggestedthat resistive index (RI) could be used as a hemodynamic parameter to measure the severity of benign prostatichyperplasia and intraprostatic pressure or bladder outlet obstruction. The aim of this study was to evaluate theeffect of a single dose 20 mg tadalafil on resistive index value in prostate zones to evaluate the mechanism ofaction of phosphodiesterase type 5-inhibitors at the prostate level.Methods: Twenty consecutive patients aged between 54-67 years with BPH-LUTS [International ProstateSymptom Score ≥ 12] and erectile dysfunction [five-item International Index of Erectile Function (IIEF)questionnaire < 22] underwent RI measurement in prostate transitional zone (TZ) and peripheral zone (PZ)using transrectal power Doppler ultrasonography baseline and within 16 hours after the administration of 20mg tadalafil. The primary study end point is the change in prostate TZ RI values.Results: The mean baseline total prostate scores and peak urinary flow were 16.2 ± 4.34 (range: 12-26) and10.45 ml/s (range: 7-13 ml/s), respectively. The mean baseline total IIEF was 12.8 ± 4.22 (range: 6-20). Themean TZ RI at baseline and after tadalafil administration were 0.4985 and 0.5497, respectively (p = 0.232).No statistically significant differences for RI changes between baseline and after the administration of a singledose 20 mg tadalafil were observed in the prostatic zones.Conclusion: A single dose 20 mg tadalafil showed no impact on prostate TZ RI.

🔖

Cite This Article

EFE, E., KÜÇÜKDURMAZ, F., ŞAHİNKANAT, T., EKERBİÇER, H. Ç. (2022). Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones. The European Research Journal, Cilt: 4 - Sayı: 4, 320–325. https://ajindex.com/articles/597757

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
  2. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
  3. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
  4. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
  5. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502- 7. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259- 63. Waldkirch ES, Uckert S, Langnase K Richter K, Jonas U, Wolf G, et al. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007;52:495-501.
  6. Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007;69:25- 6. Yencilek E, Koyuncu H, Arslan D, Bastug Y. The measurement of the prostatic resistive index is a reliable ultrasonographic tool to stratify symptoms of patients with benign prosthatic hyperplasia. Med Ultrason 2014;16:208-13.
  7. Zhang X, Li G, Wei X, Mo X, Hu L, Zha Y, et al. Resistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol 2012;188:881-7.
  8. Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol 2000;37:436-42.
  9. Tsuru N, Kurita Y, Masud